Jazz Pharmaceuticals (BSP:J2AZ34) E10: R$1.62 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:J2AZ34 Jazz Pharmaceuticals PLC BSP:J2AZ34
44 GF Score
Price R$87.12
GF Value R$51.81
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals E10?

Jazz Pharmaceuticals BSP:J2AZ34 -2.71% 44 E10 is R$1.62 as of Jun. 2026. GuruFocus rates BSP:J2AZ34 with a GF Score™ of 44/100 and a GF Value™ of R$51.81 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was R$14.245. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is R$1.62 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Jazz Pharmaceuticals's average E10 Growth Rate was -100.00% per year. During the past 3 years, the average E10 Growth Rate was 0.80% per year. During the past 5 years, the average E10 Growth Rate was -1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Jazz Pharmaceuticals was 95.60% per year. The lowest was -5.60% per year. And the median was 4.80% per year.

As of today (2026-08-08), Jazz Pharmaceuticals's current stock price is R$87.12. Jazz Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 was R$1.62. Jazz Pharmaceuticals's Shiller PE Ratio of today is 53.78.

During the past 13 years, the highest Shiller PE Ratio of Jazz Pharmaceuticals was 3414.00. The lowest was 19.06. And the median was 31.67.


Jazz Pharmaceuticals  (BSP:J2AZ34) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Jazz Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=87.12/1.62
=53.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Jazz Pharmaceuticals was 3414.00. The lowest was 19.06. And the median was 31.67.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Jazz Pharmaceuticals E10 Related Terms


Jazz Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals E10 Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Jazz Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.62

BSP:J2AZ34 vs BBIO, ASND, EXEL: E10 Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Shiller PE Ratio falls into.


BSP:J2AZ34
44GF Score
Jazz Pharmaceuticals PLC BSP:J2AZ34
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jazz Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.245/128.6700*128.6700
=14.245

Current CPI (Jun. 2026) = 128.6700.

Jazz Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201609 4.717 100.274 6.053
201612 6.406 99.676 8.269
201703 4.410 100.374 5.653
201706 5.668 100.673 7.244
201709 3.226 100.474 4.131
201712 12.488 100.075 16.056
201803 2.459 100.573 3.146
201806 5.657 101.072 7.202
201809 9.902 101.371 12.569
201812 10.252 100.773 13.090
201903 5.646 101.670 7.145
201906 17.582 102.168 22.143
201909 7.333 102.268 9.226
201912 5.295 102.068 6.675
202003 -13.779 102.367 -17.319
202006 10.688 101.769 13.513
202009 14.256 101.072 18.149
202012 11.987 101.072 15.260
202103 11.777 102.367 14.803
202106 -30.724 103.364 -38.246
202109 -4.540 104.859 -5.571
202112 -3.223 106.653 -3.888
202203 0.149 109.245 0.175
202206 2.776 112.779 3.167
202209 -1.626 113.504 -1.843
202212 -20.037 115.436 -22.334
202303 5.417 117.609 5.926
202306 7.378 119.662 7.933
202309 10.569 120.749 11.262
202312 6.958 120.749 7.414
202403 -1.145 120.990 -1.218
202406 13.411 122.318 14.107
202409 18.939 121.594 20.041
202412 18.974 122.439 19.940
202503 -8.752 123.405 -9.125
202506 -65.108 124.492 -67.293
202509 21.881 124.810 22.558
202512 17.513 125.770 17.917
202603 23.167 127.830 23.319
202606 14.245 128.670 14.245

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of R$1.62 mean?
Jazz Pharmaceuticals (BSP:J2AZ34) has a E10 of R$1.62 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' E10 too high?
Jazz Pharmaceuticals' current E10 is R$1.62. Overall, Jazz Pharmaceuticals has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' E10 compare to BBIO and ASND?
Jazz Pharmaceuticals' E10 of R$1.62 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current E10 is R$1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (BSP:J2AZ34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$51.81, compared to a current price of R$87.12 — trading 68.2% above its estimated fair value. The current E10 is R$1.62. Jazz Pharmaceuticals' overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Jazz Pharmaceuticals (BSP:J2AZ34), the current E10 is R$1.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (BSP:J2AZ34) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of R$87.12 is trading 68.2% above its estimated GF Value™ of R$51.81. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BSP:J2AZ34:

  • E10: R$1.62
  • GF Value™: R$51.81 vs. price of R$87.12 (68.2% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the BSP:J2AZ34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
44GF Score

Get the complete analysis for BSP:J2AZ34

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$87.12
Price
R$51.81
GF Value